Shopping Cart
- Remove All
Your shopping cart is currently empty
Concizumab
🥰Excellent
Catalog No. T77373Cas No. 1312299-39-0
Alias NN 7415, mAb 2021
Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that selectively binds to the Kunitz protease inhibitor (KPI) 2 domain of TFPI, blocking its interaction with the FXa active site. Injections of Concizumab increase thrombin in blood, thereby preventing and treating hemophilia.
Concizumab
Concizumab
🥰Excellent
Catalog No. T77373Alias NN 7415, mAb 2021Cas No. 1312299-39-0
Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that selectively binds to the Kunitz protease inhibitor (KPI) 2 domain of TFPI, blocking its interaction with the FXa active site. Injections of Concizumab increase thrombin in blood, thereby preventing and treating hemophilia.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $228 | In Stock | |
| 5 mg | $589 | In Stock | |
| 10 mg | $967 | In Stock | |
| 25 mg | $1,430 | In Stock | |
| 50 mg | $1,930 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreSelect Batch
Concentration:6.34 mg/mL
Purity:> 95%
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that selectively binds to the Kunitz protease inhibitor (KPI) 2 domain of TFPI, blocking its interaction with the FXa active site. Injections of Concizumab increase thrombin in blood, thereby preventing and treating hemophilia. |
| In vitro | In a concentration-dependent manner, Concizumab increases the peak value of thrombin [1]. |
| In vivo | In cynomolgus monkeys, Concizumab (i.v./s.c.) blocked the interaction between TFPI and FXa active site [2]. |
| Alias | NN 7415, mAb 2021 |
| Molecular Weight | 145.76 kDa |
| Cas No. | 1312299-39-0 |
Storage & Solubility Information
| Storage | store at low temperature | store at -80°C | Shipping with blue ice. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Concizumab | purchase Concizumab | Concizumab cost | order Concizumab | Concizumab in vivo | Concizumab in vitro | Concizumab molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.